Media ReleasesNoxopharm

View All Noxopharm News

Noxopharm, Corporate Presentation August 2017

Objective 1

To bring to market by 2022 a drug (NOX66) that:

- sensitises most forms of cancer to radiotherapy and chemotherapy

- delivers improved survival outcomes for most cancer patients

- becomes a standard-of-care drug in cancer therapy

Objective 2

To develop a pipeline of non-oncology drugs, capable of crossing into the brain, with first-in-class activity against a number of common community diseases/disorders of significant unmet.

To view Presentation please download PDF attached: 
Download this document